Copyright
©The Author(s) 2024.
World J Hepatol. Apr 27, 2024; 16(4): 640-649
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.640
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.640
Variable | HBV monoinfection (n = 644) | HBV/HDV coinfection (n = 319) | P value |
Sex | |||
Female | 41.5 | 51.7 | 0.002a |
Male | 58.5 | 48.3 | 0.002a |
Age, mean ± SD, yr | |||
Total | 51.6 ± 13.6 | 53.5 ± 11.7 | 0.03a |
Female | 51.2 ± 13.4 | 55.5 ± 11.4 | 0.002a |
Male | 51.8 ± 13.6 | 51.3 ± 11.7 | 0.67 |
Time since HBV diagnosis, mean ± SD, months | 86.2 ± 3.4 | 112.8 ± 7.1 | 0.36 |
Stage of disease at diagnosis | < 0.0001a | ||
Chronic hepatitis | 87.9 | 73.1 | |
Compensated liver cirrhosis | 9.9 | 19.4 | |
Decompensated liver cirrhosis | 2.2 | 7.5 | |
Hepatocellular carcinoma at diagnosis | 2.6 | 4.1 | 0.22 |
HBeAg-positive | 5.1 | 3.3 | 0.19 |
Liver stiffness measurement at therapy initiation, mean ± SD, kPa | 8.7 ± 3.3 | 10.9 ± 5.7 | 0.003a |
HBV DNA serum level at diagnosis, mean ± SD, IU/mL | 2994542.8 ± 3014.7 | 610025.3 ± 158.9 | < 0.0001a |
Past or current pegylated interferon-α therapy | 14.6 | 42.5 | < 0.0001a |
Current nucleos(t)ide analogue therapy | 70.3 | 36.4 | < 0.0001a |
Previous documented COVID-19 | 40.8 | 34 | 0.0003a |
Associated diabetes mellitus | 11.2 | 7.5 | 0.07 |
Variable, % | HBV monoinfection (n = 644) | HBV/HDV coinfection (n = 319) | P value |
Urban area | 59.0 | 51.5 | 0.06 |
Education level | 0.0006a | ||
No or elementary school (0 to 8 yr) | 17.6 | 24.3 | |
High school (12 yr) | 48.7 | 55.7 | |
College/university | 33.7 | 20 | |
Vaccination against HBV (any dose) | 15.6 | 12.5 | 0.25 |
Life partner vaccinated against HBV (any dose) | 26.5 | 30.3 | 0.41 |
Known family members positive for HBV/HCV/HDV (monoinfection or coinfection) | 18.4 | 20.5 | 0.48 |
Sexual contact with a partner positive for HBV/HCV/HDV (monoinfection or coinfection) | 4.6 | 12.5 | 0.0001a |
Occupation with risk of exposure to blood products | 3.9 | 6.2 | 0.17 |
Blood transfusion | 18.4 | 30 | 0.0004a |
Haemodialysis in antecedents (long-term or incidental owing to a complication in ICU) | 2.5 | 15.9 | < 0.0001a |
Any surgery before diagnosis (excluding dental surgery) | 58.1 | 52.7 | 0.16 |
At least one hospitalization before diagnosis | 82.3 | 65 | < 0.0001a |
Any dental surgery before diagnosis | 83 | 67 | < 0.0001a |
Serious accidents (work, traffic, domestic) | 8.4 | 21.3 | < 0.0001a |
Accidents with blood-contaminated objects | 5.5 | 19 | < 0.0001a |
Injections at home/outpatient unit | 4.8 | 16.7 | < 0.0001a |
Imprisonment (current or previous) | 0.2 | 15.5 | < 0.0001a |
Tattoos/any body piercing | 15 | 29.5 | < 0.0001a |
Injecting drug use | 0.5 | 10.5 | < 0.0001a |
Multiple sexual partners in the past 3 years | 15.9 | 25.6 | 0.001a |
Previous sexually transmitted diseases | 2.3 | 8.9 | < 0.0001a |
Abortions (improper conditions)1 | 3.3 | 5.9 | 0.14 |
- Citation: Iacob S, Gheorghe L, Onica M, Huiban L, Pop CS, Brisc C, Sirli R, Ester C, Brisc CM, Diaconu S, Rogoveanu I, Sandulescu L, Vuletici D, Trifan A. Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update. World J Hepatol 2024; 16(4): 640-649
- URL: https://www.wjgnet.com/1948-5182/full/v16/i4/640.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i4.640